Cases

Malignant melanoma with pet positive femur lesion- what OT-RADS would you give

Yes Since dwi is so bright with adc of 0.5 pet positive and incr perfusion I left it as OT-RADS III- probably benign and can be followed up rather than OT-RADS II- definitely benign. Playing safe but I agree its likely just red marrow Best! AC Avneesh Chhabra, M.D. M.B.A. Professor, Radiology & Orthopedic Surgery

Loading

Malignant melanoma with pet positive femur lesion- what OT-RADS would you give Read More »

Malignant melanoma with pet positive femur lesion- what OT-RADS would you give

Avneesh Chhabra, M.D. M.B.A. Professor Radiology & Orthopedic Surgery Chief, Division of Musculoskeletal Radiology UT Southwestern Medical Center, Dallas, Tx 5373 Harry Hines Blvd. Dallas, Tx-75390-9178 Office: 214-648-2122 avneesh.chhabra@utsouthwestern.edu www.utsouthwestern.edu​ ________________________________ UT Southwestern Medical Center The future of medicine, today.

Loading

Malignant melanoma with pet positive femur lesion- what OT-RADS would you give Read More »

Status post TMJ arthroscopy- what is abnormal on left and NS-RADS?

IMPRESSION: Findings of traction neuropathy of the posterior branch of the mandibular nerve as it traverses posterior to the TM joint on the left. 3-D images enclosed NS-RADS: Nerve: I2 – Injury Sunderland class 2, Muscle: U – Unremarkable Avneesh Chhabra, M.D. M.B.A. Professor Radiology & Orthopedic Surgery Chief, Division of Musculoskeletal Radiology UT Southwestern

Loading

Status post TMJ arthroscopy- what is abnormal on left and NS-RADS? Read More »

Quiz 2d and 3D near sural nerve

Avneesh Chhabra, M.D. M.B.A. Professor Radiology & Orthopedic Surgery Chief, Division of Musculoskeletal Radiology UT Southwestern Medical Center, Dallas, Tx 5373 Harry Hines Blvd. Dallas, Tx-75390-9178 Office: 214-648-2122 avneesh.chhabra@utsouthwestern.edu www.utsouthwestern.edu​ ________________________________ UT Southwestern Medical Center The future of medicine, today.

Loading

Quiz 2d and 3D near sural nerve Read More »